Difficulty: Medium
Average Score: 83%
Practice
A provider may consider testing for CYP2D6 variants prior to starting tamoxifen for breast cancer to:
Correct answer
B
Rationale
CYP2D6 testing identifies poor metabolizers who may not convert tamoxifen to its active form (endoxifen), impacting efficacy, not just ADRs or interactions .